ClinicalTrials.gg
CompletedNCT05643534Updated Sep 22, 2026

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

A Phase 3 interventional study of Tenapanor 50 MG and Tenapanor 25 mg bid in Irritable Bowel Syndrome With Constipation (IBS-C), sponsored by Ardelyx. Completed at 39 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
7th of 11
180 · median 186
Started
2022
the only one that year
Phase 3
7 of 11
2 open now
Registered
6th of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 3, and was the 6th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.

Read the detailed description

This study consists of 2-week screening period followed by 12 week randomized treatment period (RTP) and a 2-week treatment-free Follow-Up period (only for patients who will not enter the 40-week Long Term Safety Extension Study [TEN-01-306]). At the beginning of the 2-week Screening period, patients who provide written assent will be fully assessed for eligibility into the study and will be asked to self-report daily information about the status of their IBS symptoms via an electronic diary (eDiary) device. Patient compliance with the eDiary will be monitored actively by the site staff and will be reviewed to determine eligibility at the end of screening. Eligible patients will be randomized to receive one of the study medications: tenapanor 25 mg BID, tenapanor 50 mg BID, or placebo.

During the 12-week double-blind RTP, patients will continue recording daily assessments via the eDiary system as instructed and compliance with eDiary entries will be monitored on an ongoing basis. Patients will return for study visit every two or four weeks (Visits 3-6) and will undergo safety assessments at these visits.

Patients who do not enter the 40-week Long Term Safety Extension Study [TEN-01-306] including those who complete the RTP but do not enter study TEN-01-306 and those who prematurely discontinue from the RTP, a Follow-Up Visit will be scheduled approximately 2 weeks after the completion of the RTP (Visit 6) or the Early Termination Visit at which safety assessments will be performed

03

Conditions studied

  • Irritable Bowel Syndrome With Constipation (IBS-C)

Keywords

  • IBS-C
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥12 and \<18 years old
  • Patient weighs ≥18 kg at the time the patient provides written assent
  • Females of must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate (including abstinence).
  • Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C
  • Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement)
  • Patient meets the entry criteria assessed during the 2-week Screening period.
  • Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device
  • Patient must provide written assent and the parent/guardian/LAR must provide written before the initiation of any study-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Functional diarrhea as defined by Rome IV child/adolescent criteria
  • IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria
  • History of non-retentive fecal incontinence.
  • Required manual disimpaction any time prior to randomization (after consent);
  • Has both unexplained and alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process
  • Patient has any of the following conditions:

    • Celiac disease, or positive serological test for celiac disease
    • Cystic fibrosis
    • Hypothyroidism that is untreated or treated with thyroid hormone
    • Down's syndrome or any other chromosomal disorder
    • Active anal fissure
    • Anatomic malformations (eg, imperforate anus)
    • Intestinal nerve or muscle disorders (eg, Hirschprung disease)
    • Neuropathic conditions (eg, spinal cord abnormalities)
    • Lead toxicity, hypercalcemia
    • Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device)
    • Inflammatory bowel disease
    • Childhood functional abdominal pain syndrome
    • Childhood functional abdominal pain;
    • Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study;
    • Lactose intolerance that is associated with abdominal pain or discomfort
    • History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the has been in a complete remission for at least 5 years before the Randomization Visit.)
    • History of diabetic neuropathy.
  • Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator.
  • Patient has had surgery that meets any of the following criteria:

    • Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit;
    • Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit;
    • An appendectomy or cholecystectomy during the 60 days before the Screening Visit;
    • Other major surgery during the 30 days before the Screening Visit
  • History of alcohol or substance abuse
  • Participation in other clinical trials within 1 month prior to Screening
  • Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial
  • If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Tenpanor 50 mg BID

    Patients will be randomized to receive 50 mg tenapanor twice daily

    Drug: Tenapanor 50 MG

  • Experimental
    Tenpanor 25 mg BID

    Patients will be randomized to receive 25 mg tenapanor twice daily

    Drug: Tenapanor 25 mg bid

  • Placebo comparator
    Placebo Comparator

    Patients will be randomized to receive matching placebo twice daily

    Drug: Placebo

Interventions

  • Participants will receive tenapanor 50 mg BID (total of 100 mg daily)

  • Participants will receive tenapanor 25 mg BID (total of 50 mg daily)

  • DrugPlacebo

    Participants will be randomized to receive matching placebo

06

What researchers measure

Primary outcomes

  1. 6/12-week APS (abdominal pain and SBM) +2 response

    6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for ≥6 out of the 12 weeks of the RTP. * The weekly SBM +2 response is defined as having an increase of ≥2 from baseline in the average weekly SBM frequency for a given week * The weekly abdominal pain response is defined as having ≥30% reduction from baseline in the average weekly abdominal pain score for a given week

    Time frame: 12 weeks

Secondary outcomes

  1. 6/12-week SBM +2 response

    6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for ≥6 out of the 12 weeks of the RTP

    Time frame: 12 weeks

  2. 6/12-week abdominal pain response

    6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for ≥6 out of the 12 weeks of the RTP

    Time frame: 12 weeks

  3. Change from baseline in average weekly SBM frequency

    Change from baseline in average weekly SBM frequency

    Time frame: 12 weeks

  4. Change from baseline in average weekly stool consistency score

    Change from baseline in average weekly stool consistency score

    Time frame: 12 weeks

  5. Change from baseline in average weekly abdominal pain score

    Change from baseline in average weekly abdominal pain score

    Time frame: 12 weeks

  6. Overall use of rescue medication

    Overall use of rescue medication

    Time frame: 12 weeks

07

Study locations

39 sites
  • G & L Research, LLC
    Foley, Alabama 36535, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72205, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • I.H.S. Health, LLC
    Kissimmee, Florida 34741, United States
  • Waterway Research & Associates Corp
    Miami, Florida 33155, United States
  • Valencia Medical and Research Center
    Miami, Florida 33165, United States
  • Orlando Health, Inc.- APH Center for Digestive Health and Nutrition
    Orlando, Florida 32806, United States
  • Florida Pharmaceutical Research and Associates, Inc.
    South Miami, Florida 33143, United States
  • Clinical Research Institute
    Stockbridge, Georgia 30281, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Riley Children's Health IUH
    Indianapolis, Indiana 46202, United States
  • Maine Health
    Portland, Maine 04102, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Mankato Clinic/ Javara Research Ltd
    Mankato, Minnesota 56001, United States
  • Boys Town National Research Hospital
    Boys Town, Nebraska 68010, United States
  • Med Clinical Research Partners, LLC
    Irvington, New Jersey 07111, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Advantage Clinical Trials
    The Bronx, New York 10467, United States
  • Atrium Health
    Charlotte, North Carolina 28203, United States
  • Duke University School of Medicine
    Durham, North Carolina 27705, United States
  • Wilmington Health
    Wilmington, North Carolina 28401, United States
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Prisma Health Children's Hospital
    Greenville, South Carolina 29615, United States
  • Advance Clinical Trial PLLC
    Abilene, Texas 79606, United States
  • Maspons Pediatric Gastro
    El Paso, Texas 79902, United States
  • Proactive El Paso, LLC
    El Paso, Texas 79902, United States
  • Texas Digestive Specialists
    Harlingen, Texas 78550, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Pioneer Research Solutions Inc
    Sugar Land, Texas 77479, United States
  • ClinPoint Trials
    Waxahachie, Texas 75165, United States
  • University Physicians and Surgeons, Inc.
    Huntington, West Virginia 25701, United States
  • Frontier Clinical Research
    Kingwood, West Virginia 26537, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2026, 45 months.

Of 28 industry-sponsored phase 3 interventional studies under Constipation, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 45 months is above that.

Counting every sponsor, half of 36 studies reached it within 21 months; a quarter within 10 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 8, 2022
StartActual
Nov 15, 2022
Primary completionActual
Aug 20, 2026
CompletionActual
Aug 20, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05643534
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Nov 15, 2022
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update
Sep 22, 2026

Study contacts

Jocelyn Tabora
study director · Ardelyx

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion